An independent review board (United States [US]) or ethics committee (ex-US sites) at each study site approved the study protocol and its amendments. The study was conducted in accordance with ethical ...
The decision to discontinue the program was based on data indicating “insufficient efficacy in the target population.” Johnson & Johnson is ending the phase 3 VENTURA clinical development program ...
On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Johnson & Johnson has decided to halt the development of selective kappa opioid receptor (KOR) antagonist aticaprant as a treatment for major depressive disorder (MDD), blowing a hole in its ...
Please provide your email address to receive an email when new articles are posted on . The study included 166 adults with major depressive disorder randomized to receive aticaprant or placebo. At 6 ...
Johnson & Johnson once tipped aticaprant to generate peak sales of up to $5 billion a year. (iStock / Getty Images Plus) Johnson & Johnson has added to the opioid kappa blues. Months after Neumora ...
March 6 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Johnson & Johnson's 2030 sales goal will rely, in part, on successfully developing new treatments for depression. (Jolygon/Getty Images) Johnson & Johnson expects neuroscience to play a pivotal role ...
Johnson & Johnson (JNJ Quick Quote JNJ - Free Report) decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an adjunctive treatment for major depressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results